XML 37 R25.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes (Tables)
6 Months Ended
Dec. 31, 2016
Income Taxes  
Reconciliation of the Company's expected tax benefit, as computed by applying the U.S. federal corporate tax rate to loss before the benefit for income taxes, and actual tax

The difference between the Company’s expected tax benefit, as computed by applying the U.S. federal corporate tax rate of 34% to loss before the benefit for income taxes, and actual tax is reconciled in the following chart (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

Year Ended June 30,

 

 

 

2016

    

2016

 

2015

 

2014

 

Loss before income tax expense

    

$

(78,883)

    

$

(144,817)

    

$

(60,739)

    

$

(71,364)

 

Expected tax benefit at 34%

  

$

(26,820)

 

$

(49,238)

 

$

(20,651)

 

$

(24,264)

 

Permanent differences

 

 

15

 

 

345

 

 

818

 

 

215

 

Incentive stock options

 

 

1,313

 

 

2,501

 

 

1,948

 

 

1,738

 

State tax benefit net of federal benefit

 

 

(4,157)

 

 

(7,954)

 

 

(3,252)

 

 

(4,062)

 

Increase in valuation allowance, net

 

 

32,922

 

 

62,505

 

 

27,940

 

 

26,011

 

Federal research credit

 

 

(1,232)

 

 

(4,109)

 

 

(1,407)

 

 

(1,002)

 

Federal orphan drug credit

 

 

(2,901)

 

 

(4,241)

 

 

(5,471)

 

 

 —

 

Expired loss and credit carryforwards

 

 

 —

 

 

184

 

 

75

 

 

1,364

 

Stock option expirations

 

 

860

 

 

7

 

 

 —

 

 

 —

 

Benefit for income taxes

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

 

Schedule of significant components of deferred tax assets

Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2016, and June 30, 2016 and 2015 are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

June 30,

 

 

 

2016

 

2016

 

2015

 

Deferred tax assets:

    

 

 

    

 

 

    

 

 

 

Net operating loss carryforwards

 

$

167,869

 

$

139,791

 

$

89,362

 

Research and development tax credit carryforwards

 

 

43,096

 

 

36,879

 

 

25,131

 

Property and other intangible assets

 

 

2,982

 

 

2,395

 

 

2,532

 

Deferred revenue

 

 

13,205

 

 

12,911

 

 

16,179

 

Stock-based compensation

 

 

16,794

 

 

16,033

 

 

11,379

 

Deferred lease incentive

 

 

4,264

 

 

4,356

 

 

4,279

 

Other liabilities

 

 

2,107

 

 

3,726

 

 

3,177

 

Royalty sale

 

 

73,973

 

 

75,956

 

 

78,427

 

Total deferred tax assets

 

$

324,290

 

$

292,047

 

$

230,466

 

 

 

 

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

 

 

Accounting method change

 

 

 —

 

 

(492)

 

 

(983)

 

Royalty sale transaction costs

 

 

(1,569)

 

 

(1,757)

 

 

(2,190)

 

Total deferred tax liabilities

 

$

(1,569)

 

$

(2,249)

 

$

(3,173)

 

Valuation allowance

 

 

(322,721)

 

 

(289,798)

 

 

(227,293)

 

Net deferred tax assets/(liabilities)

 

$

 —

 

$

 —

 

$

 —